CT Perfusion Images in Assessing Treatment Response in Patients With Pancreatic Cancer

Evaluation of CT Perfusion Parameters as a Potential Biomarker for Treatment Response in Pancreatic Cancer

This pilot clinical trial studies how well computed tomography (CT) perfusion images work in assessing treatment response in patients with pancreatic cancer. Analyzing specific measurements on the CT perfusion images may help doctors better determine how a tumor responds to chemotherapy and/or radiation therapy and may help guide treatment for patients with pancreatic cancer.

OUTLINE:

Patients undergo CT perfusion sequence during the first 40 seconds of the baseline standard of care CT scan and during follow-up CT scans at 2 and possibly 4 months after chemotherapy, at 4-6 weeks after radiation therapy, or prior to definitive surgery.

After completion of the study, patients are followed up periodically for 2 years.

Inclusion Criteria:

• Signed informed consent form
• A diagnosis of pancreatic ductal adenocarcinoma

Exclusion Criteria:

• Patients unable to provide informed consent
• Women who are pregnant or intending to become pregnant during the study
• Patients with body mass index greater than 40 kg/m^2
• History of severe allergic-like reaction to iodinated contrast media